We are not going to see any real sp appreciation until there is tangible evidence of the project moving forward, a clear pathway to production and details on revenue streams. Until then it is speculative potential and will be valued as such. Details around production and binding offtakes will enable the market to apply a valuation and attract institutions to capitalise on an opportunity to make profit.
Ann: Strategic Investment from Sichuan Hebang Biotechnology, page-67
-
- There are more pages in this discussion • 206 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AEV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.9¢ |
Change
-0.001(5.26%) |
Mkt cap ! $24.33M | |||
| Open | High | Low | Value | Volume |
| 0.9¢ | 0.9¢ | 0.9¢ | $3.752K | 416.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 2796798 | 0.9¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.0¢ | 300000 | 1 |
View Market Depth
| Last trade - 13.54pm 12/11/2024 (20 minute delay) ? |
| AEV (ASX) Chart |